schliessen

Filtern

 

Bibliotheken

A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.

OBJECTIVETo determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial. METHODSA multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acoti... Full description

Journal Title: Gut June 2012, Vol.61(6), pp.821-828
Main Author: Matsueda, Kei
Other Authors: Hongo, Michio , Tack, Jan , Saito, Youichi , Kato, Hiroki
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1468-3288 ; DOI: 10.1136/gutjnl-2011-301454
Link: http://search.proquest.com/docview/1011198426/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1011198426
title: A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
format: Article
creator:
  • Matsueda, Kei
  • Hongo, Michio
  • Tack, Jan
  • Saito, Youichi
  • Kato, Hiroki
subjects:
  • Adult–Therapeutic Use
  • Benzamides–Therapeutic Use
  • Cholinesterase Inhibitors–Drug Therapy
  • Double-Blind Method–Drug Effects
  • Dyspepsia–Therapeutic Use
  • Eating–Therapeutic Use
  • Female–Therapeutic Use
  • Humans–Therapeutic Use
  • Male–Therapeutic Use
  • Postprandial Period–Therapeutic Use
  • Thiazoles–Therapeutic Use
  • Time Factors–Therapeutic Use
  • Treatment Outcome–Therapeutic Use
  • Abridged
  • Benzamides
  • Cholinesterase Inhibitors
  • Thiazoles
  • Z 338
ispartof: Gut, June 2012, Vol.61(6), pp.821-828
description: OBJECTIVETo determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial. METHODSA multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three meal-related symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored. RESULTS52.2% of those receiving acotiamide and 34.8% in the placebo group (p
language: eng
source:
identifier: E-ISSN: 1468-3288 ; DOI: 10.1136/gutjnl-2011-301454
fulltext: fulltext
issn:
  • 14683288
  • 1468-3288
url: Link


@attributes
ID141599778
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1011198426
sourceidproquest
recordidTN_proquest1011198426
sourcesystemPC
pqid1011198426
galeid296561773
display
typearticle
titleA placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
creatorMatsueda, Kei ; Hongo, Michio ; Tack, Jan ; Saito, Youichi ; Kato, Hiroki
contributorMatsueda, Kei (correspondence author) ; Matsueda, Kei (record owner)
ispartofGut, June 2012, Vol.61(6), pp.821-828
identifierE-ISSN: 1468-3288 ; DOI: 10.1136/gutjnl-2011-301454
subjectAdult–Therapeutic Use ; Benzamides–Therapeutic Use ; Cholinesterase Inhibitors–Drug Therapy ; Double-Blind Method–Drug Effects ; Dyspepsia–Therapeutic Use ; Eating–Therapeutic Use ; Female–Therapeutic Use ; Humans–Therapeutic Use ; Male–Therapeutic Use ; Postprandial Period–Therapeutic Use ; Thiazoles–Therapeutic Use ; Time Factors–Therapeutic Use ; Treatment Outcome–Therapeutic Use ; Abridged ; Benzamides ; Cholinesterase Inhibitors ; Thiazoles ; Z 338
descriptionOBJECTIVETo determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial. METHODSA multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three meal-related symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored. RESULTS52.2% of those receiving acotiamide and 34.8% in the placebo group (p<0.001) were classified as responders according to a global assessment of OTE. Over 4 weeks, the elimination rate for all three meal-related symptoms was 15.3% among patients receiving...
languageeng
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1011198426/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Matsueda, Kei
1Hongo, Michio
2Tack, Jan
3Saito, Youichi
4Kato, Hiroki
titleA placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
descriptionOBJECTIVETo determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial. METHODSA multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three meal-related symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored. RESULTS52.2% of those receiving acotiamide and 34.8% in the placebo group (p<0.001) were classified as responders according to a global assessment of OTE. Over 4 weeks, the elimination rate for all three meal-related symptoms was 15.3% among patients receiving...
subject
0Adult–Therapeutic Use
1Benzamides–Therapeutic Use
2Cholinesterase Inhibitors–Drug Therapy
3Double-Blind Method–Drug Effects
4Dyspepsia–Therapeutic Use
5Eating–Therapeutic Use
6Female–Therapeutic Use
7Humans–Therapeutic Use
8Male–Therapeutic Use
9Postprandial Period–Therapeutic Use
10Thiazoles–Therapeutic Use
11Time Factors–Therapeutic Use
12Treatment Outcome–Therapeutic Use
13Abridged
14Benzamides
15Cholinesterase Inhibitors
16Thiazoles
17Z 338
18NCT00761358
19ClinicalTrials.gov
general
0English
110.1136/gutjnl-2011-301454
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1011198426
issn
014683288
11468-3288
rsrctypearticle
creationdate2012
addtitleGut
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorMatsueda, Kei
startdate20120601
enddate20120601
citationpf 821 pt 828 vol 61 issue 6
lsr30VSR-Enriched:[galeid, issn, pqid]
sort
titleA placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
authorMatsueda, Kei ; Hongo, Michio ; Tack, Jan ; Saito, Youichi ; Kato, Hiroki
creationdate20120601
lso0120120601
facets
frbrgroupid3033011175617525708
frbrtype5
newrecords20181218
languageeng
creationdate2012
topic
0Adult–Therapeutic Use
1Benzamides–Therapeutic Use
2Cholinesterase Inhibitors–Drug Therapy
3Double-Blind Method–Drug Effects
4Dyspepsia–Therapeutic Use
5Eating–Therapeutic Use
6Female–Therapeutic Use
7Humans–Therapeutic Use
8Male–Therapeutic Use
9Postprandial Period–Therapeutic Use
10Thiazoles–Therapeutic Use
11Time Factors–Therapeutic Use
12Treatment Outcome–Therapeutic Use
13Abridged
14Benzamides
15Cholinesterase Inhibitors
16Thiazoles
17Z 338
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Matsueda, Kei
1Hongo, Michio
2Tack, Jan
3Saito, Youichi
4Kato, Hiroki
jtitleGut
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Matsueda
1Hongo
2Tack
3Saito
4Kato
aufirst
0Kei
1Michio
2Jan
3Youichi
4Hiroki
au
0Matsueda, Kei
1Hongo, Michio
2Tack, Jan
3Saito, Youichi
4Kato, Hiroki
addauMatsueda, Kei
atitleA placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
jtitleGut
risdate20120601
volume61
issue6
spage821
epage828
pages821-828
eissn1468-3288
formatjournal
genrearticle
ristypeJOUR
abstractOBJECTIVETo determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial. METHODSA multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three meal-related symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored. RESULTS52.2% of those receiving acotiamide and 34.8% in the placebo group (p<0.001) were classified as responders according to a global assessment of OTE. Over 4 weeks, the elimination rate for all three meal-related symptoms was 15.3% among patients receiving...
doi10.1136/gutjnl-2011-301454
urlhttp://search.proquest.com/docview/1011198426/
issn00175749
date2012-06-01